Cargando…
Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression
BACKGROUND: Recent clinical trials on ovarian cancer with mifepristone (MF) have failed, despite in vitro findings on its strong progesterone (P4) antagonist function. METHODS: Ovarian cancer human and murine cell lines, cultured high-grade human primary epithelial ovarian cancer (HG-hOEC) cells and...
Autores principales: | Ponikwicka-Tyszko, Donata, Chrusciel, Marcin, Stelmaszewska, Joanna, Bernaczyk, Piotr, Chrusciel, Paulina, Sztachelska, Maria, Scheinin, Mika, Bidzinski, Mariusz, Szamatowicz, Jacek, Huhtaniemi, Ilpo T., Wolczynski, Slawomir, Rahman, Nafis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796594/ https://www.ncbi.nlm.nih.gov/pubmed/31466918 http://dx.doi.org/10.1016/j.ebiom.2019.08.035 |
Ejemplares similares
-
Mifepristone Treatment Promotes Testicular Leydig Cell Tumor Progression in Transgenic Mice
por: Ponikwicka-Tyszko, Donata, et al.
Publicado: (2020) -
Extragonadal FSHR Expression and Function—Is It Real?
por: Chrusciel, Marcin, et al.
Publicado: (2019) -
Revisiting the expression and function of follicle-stimulation hormone receptor in human umbilical vein endothelial cells
por: Stelmaszewska, Joanna, et al.
Publicado: (2016) -
GnRH antagonist treatment of malignant adrenocortical tumors
por: Doroszko, Milena, et al.
Publicado: (2018) -
Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy
por: Sztachelska, Maria, et al.
Publicado: (2022)